$SRPT We are on the brink of a significant expansion of the #ELEVIDYS label. This development has been highly anticipated, and it will open up new avenues for growth and more importantly holds great promise for the #DMD community.

$RHHBY $SRPT Comissão de Saúde 'Theme: 'Authorization by Anvisa (Brazilian Health Regulatory Agency) of the drug #Elevidys in the treatment of #Duchenne muscle dystrophy disease'' 💪 youtube.com/watch?v=2Fnzh9…

$SRPT ELEVIDYS, achieved nearly $134.0M in net product revenue in the quarter

Although its initial label is quite narrow, ELEVIDYS has posted cumulative sales of over $334.0M since its approval in June of last year, far exceeding performance of all other gene therapies…

$SRPT sales team with wide experience, is ready to get #Elevidys to a large #DMD population post the FDA label expansion

Unfortunately, those who are thinking that they are intelligent, don't understand #DMD at all, just an empty words, and it's all around their greed.

$SRPT spent over a billion dollar on development & manufacturing to bring Elevidys to #DMD patients!

“Imminently and sooner than previously indicated”. Douglas Ingram CEO comment regarding FDA at opening remarks to the potential label expansion of #ELEVIDYS . Exciting open to the CC. Each analyst scampering to ask a question that will actually be answered. $SRPT 🔥

$SRPT Q1 net product revenues $359.5M. ↑ 55% over the same quarter of the prior year
ELEVIDYS net revenues $134M.
Cash, cash equivalents $1.44B

$SRPT Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments

Net product revenues for the first quarter 2024 totaled $359.5 million, a 55% increase over the same quarter of the prior year

ELEVIDYS net revenues for the quarter…

$RHHBY $SRPT #Elevidys #Duchenne #GeneTherapy #RareDisease 💪

$SRPT should receive a draft label of # Elevidys shortly
So, will not take any questions & stay in a quiet period.

Doug CC opening:
.As you know, we have submitted a BLA supplement expand the label population for #DMD drug #Elevidys , we were recently informed by the FDA that

$SRPT's partner Roche $RHHBY keep working hard to get #Elevidys approval in Brazil
ANVISA is the Brazilian FDA equivalent
Decision in July!

Discussion at 'Health Commission' 04/30/2024 LOCATION: Annex II, Plenary 07 TIME: 09 am TOPIC: 'Authorization by ANVISA of the drug…

One more day & we will see if $SRPT can bring any surprise to the Q1-2024 earnings!

Analysts will focus on #Elevidys revenue, but the street is interested in one thing!!! FDA approval & label expansion for all #DMD ambulant patients!

LRK confirming “draft letter sooner than they had indicated” regarding FDA action on #ELEVIDYS . $SRPT

MS $SRPT 1Q24 Earnings: Elevidys Label
Expansion Progressing Ahead of
Expectations; Raising PT to $165

$SRPT Doug on the call yesterday went in length to explain what Dr. Marks is bringing in to the FDA & how his vision is related to #Elevidys decision that will be out sooner than 06/21

'As we all know, Dr. Peter Marks, the FDA CBER center director, has publicly and repeatedly…

$SRPT 'As Luis and Manuela sighed in relief, they saw a new Lucas emerge.' 💪💪💪 #Elevidys #GeneTherapy #Duchenne #RareDisease Boston Children's Lucas receives gene therapy for DMD and finds his super muscles answers.childrenshospital.org/dmd-gene-thera…

$srpt
$xbi
Net product revenues for the first quarter 2024 totaled $359.5 million , a 55% increase over the same quarter of the prior year
ELEVIDYS net revenues for the quarter totaled $133.9 million
Achieved GAAP Earnings of $36.1 million for the first quarter 2024

Joe $SRPT given $131m for the second qtr after approval for 4-5 yr olds, even if expansion is only for ambulatory would expect them to hit a $2B+ run rate by Q4 of this year for elevidys alone given they already have a lot of payers already onboard. PPS tomorrow will be much higher

$SRPT (very end) 'Future research will investigate the impact of combination therapies in patients with DMD - preclinical and clinical studies are currently in progress'; also Dr. Proud discusses #Elevidys #GeneTherapy more in the middle of vid. #Duchenne youtube.com/watch?v=Rkh-Kx…

$SRPT's partner in the EU $RHHBY Roche continue working with the EMA & #Elevidys in DMD (EMBARK): EU filing is part of 2024 plan!